| Welcoming Remarks |
Minimizing the Potential for Metabolic Activation as an Integral Part of Drug Design
David C. Evans, Merck, Rahway, NJ |
Recent Advances in Extrapolating Preclinical ADME Data to Humans
Keith Ward, GlaxoSmithKline, King of Prussia, PA |
Break |
Cytochrome P450 Reaction Phenotyping Study of Hp184 in Human Liver Microsomes
Lijuan Wang, Yongqing Huang and Peter S King, sanofi-aventis, Bridgewater, NJ |
Glucuronosyltransferases (UGTs): Several recent examples in drug development
Donglu Zhang, Bristol-Myers Squibb, Princeton, NJ |